Navigation Links
New technology delivers sustained release of drugs for up to 6 months
Date:8/13/2012

A new technology which delivers sustained release of therapeutics for up to six months could be used in conditions which require routine injections, including diabetes, certain forms of cancer and potentially HIV/AIDS.

Researchers from the University of Cambridge have developed injectable, reformable and spreadable hydrogels which can be loaded with proteins or other therapeutics. The hydrogels contain up to 99.7% water by weight, with the remainder primarily made up of cellulose polymers held together with cucurbiturils - barrel-shaped molecules which act as miniature 'handcuffs'.

"The hydrogels protect the proteins so that they remain bio-active for long periods, and allow the proteins to remain in their native state," says Dr Oren Scherman of the Department of Chemistry, who led the research. "Importantly, all the components can be incorporated at room temperature, which is key when dealing with proteins which denature when exposed to high heat."

The hydrogels developed by Scherman, Dr Xian Jun Loh and PhD student Eric Appel are capable of delivering sustained release of the proteins they contain for up to six months, compared with the current maximum of three months. The rate of release can be controlled according to the ratio of materials in the hydrogel.

Not only do these hydrogels double the window of content release, they use far less non-water material than current technology. The extra material serves as a type of scaffolding holding the hydrogel together, but it can affect performance of the cargo contained within it, so the less structure-forming material contained within the hydrogel, the more effectively it will perform.

As drug therapy moves away from small molecule drugs toward protein-based therapy, applications such hormone therapy, wound healing and insulin treatment would all be ideal applications for the hydrogels.

For example, more than a quarter of the 2.9 million individuals in the UK who have diabetes have to inject themselves daily with insulin in order to control blood glucose levels. Containing the insulin within a hydrogel could potentially reduce the number of annual injections from 365 to just two.

The long-term sustained release would be especially useful in resource-deprived or rural settings where patients requiring daily medication may not have regular access to a doctor. "There's been a lot of research that shows patients who need to take a pill each day for the rest of their lives, especially HIV patients in Africa who do not show any obvious symptoms, will take the pills for a maximum of six months before they stop, negating the point of taking the medication in the first place," says Appel. "If patients only have to take one shot which will give them six month's worth of medication, we'll have a much greater chance of affecting an entire population and slowing or stopping the progression of a disease."

The team are currently working with researchers from the Brain Repair Centre in the Department of Clinical Medicine on how the technology might be used as a possible treatment for brain cancer.

The research was published recently in the journal Biomaterials and has been patented by Cambridge Enterprise, the University's commercialisation group.


'/>"/>

Contact: Sarah Collins
sarah.collins@enterprise.cam.ac.uk
44-122-376-0335
Cambridge Enteprise University of Cambridge
Source:Eurekalert

Related biology technology :

1. Astrix Technology Group Awarded Department of Homeland Security BioWatch Laboratory Staffing Contract
2. Global Marine Biotechnology Industry
3. Frost & Sullivan Recognizes MicroProtein Technologies for its Path-Breaking Production Technology for Recombinant Proteins in Bacteria
4. First Plant Genomics Yield Technology Progresses
5. RIT professor receives National Science Foundation grant to improve on-chip networks with wireless technology
6. Verenium Corporation And Alexandria Real Estate Equities, Inc. Celebrate The Grand Opening Of A New State-of-the-art Biotechnology Facility
7. Afraxis and PsychoGenics Form Alliance to Offer Afraxis ESP Technology for Drug Discovery
8. Shape-shifting materials are goal of new nanotechnology project
9. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
10. Life Technologies to Accelerate Development of Ion Torrent Semiconductor Technology for Proteomic Applications in Research, Applied and Clinical Markets
11. New silk technology preserves heat-sensitive drugs for months without refrigeration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , December 5, 2016 The ... with almost $108 billion of revenue and some $890 ... were spent on global biopharmaceuticals, and this figure is ... Stock-Callers.com has lined up these four equities for assessment: ... Pharmaceuticals Inc. (NASDAQ: ACAD ), Acorda Therapeutics ...
(Date:12/2/2016)... ... December 02, 2016 , ... In anticipation of AxioMed’s exclusive ... production, company President, Jake Lubinski will be traveling to Switzerland from December 5-10. ... Bern, Lucerne, and Zurich to discuss the benefits of a viscoelastic disc. AxioMed ...
(Date:12/2/2016)... Research and Markets has announced the addition of Jain ... to their offering. ... , An increasing ... anticipated. Nanotechnology will be applied at all stages of drug ... in clinical trials. Many of the assays based on nanobiotechnology ...
(Date:12/2/2016)... York, NY (PRWEB) , ... December 01, 2016 , ... ... event is expanding to three days and will take place on February 1-3, 2017 ... (GSK) and Dr James Gulley (NCI), the program provides a unique 360-degree approach, which ...
Breaking Biology Technology:
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
(Date:6/27/2016)... June 27, 2016 Research and Markets has ... 2016-2020" report to their offering. ... America to grow at a CAGR of 12.28% during ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:6/21/2016)... 2016 NuData Security announced today that Randy ... principal product architect and that Jon Cunningham ... development. Both will report directly to Christopher ... reflect NuData,s strategic growth in its product and ... demand and customer focus values. ...
Breaking Biology News(10 mins):